PRAX - CONSENSUS CO - Praxis Precision Medicines

Praxis Precision Medicines (PRAX) develops high-precision therapies for severe psychiatric and neurological disorders, leveraging the success of key drug candidates in late-stage trials. This chart shows the asset value is currently at 635.98. Meanwhile, supply chain disruptions and sanctions are hindering research efforts. The startup is currently focusing on its own R&D while seeking a major partner to bring its products to market.

Praxis Precision Medicines (PRAX) is burning through its existing capital on costly clinical trials for anti-epileptic drugs in the absence of revenue. The consensus forecast integrates DCF models and industry risks from leading investment banks into a single average target. Investors should view this indicator as an integral barometer of the asset's fair value. The historical trend of analyst targets reflects a reassessment of the company's prospects. This benchmark helps avoid impulsive trades.